Last reviewed · How we verify

NCT03337763

A Prospective Pilot Study (BIO|SELECT Pilot)

Completed Last updated 27 January 2021
What this trial tests

trial in Heart Failure in 201 participants. Completed in 7 October 2019.

Timeline
7 November 2017
Primary endpoint
7 October 2019
7 October 2019

Quick facts

Lead sponsorBiotronik SE & Co. KG
StatusCompleted
Study typeOBSERVATIONAL
Enrollment201
Start date7 November 2017
Primary completion7 October 2019
Estimated completion7 October 2019
Sites1 location across Japan

Conditions studied

Sponsor

Biotronik SE & Co. KG — full company profile →

Who can join

20 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Enrolled patients implanted with Biotronik CRT-D and QP lead equipped with MultiPole pacing mode is grouped into which programmed into MultiPole pacing, or conventional bi-ventricular pacing mode. They are followed up by seven month post implantation, and predefined cardiac functional parameters are collected at each visit.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Intracardiac conduction time as a predictor of cardiac resynchronization therapy response: Results of the BIO|SELECT pilot study.
    Soejima K, Kondo Y, Sasaki S, Adachi K, et al · · 2021 · cited 4× · PMID 34988503 · DOI 10.1016/j.hroo.2021.09.007

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Biotronik SE & Co. KG trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03337763.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing